| Author/Treatment | Efficacy Response (%) | Survival (Probability %) | |||||||
| OR | SD | PFS Median | OS Median | PFS 6 months | OS 6 months | PFS 12 months | OS 12 months | 2 years | |
| Chamberlain et al. 2006 [31] Cyclophosphamide | 23 | 40 | 4 | 8 | 30 | __ | 8 | 8 |
|
| Chamberlain et al. 2008 [32] CPT-11 | 13 | 85 | 4.1 | 6.9 | 40 | __ | 5 | 23 |
|
| Yung et al. 1999 [22] Temozolomide after first relapse | 33 | 31 | 5.5 | 14.2 | 49 | 78 | 24 | 56 |
|
| Burzynski et al. 2015 Antineoplastons A10 and AS2-1 Anaplastic Astrocytoma Group | 41 | 25 | 5.4 | 25.4 | 41.7 | 83.3 | 25.0 | 58.3 | 50.0 |